Home

Femasys Inc. - Common Stock (FEMY)

0.8000
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 9th, 11:07 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.8000
Open0.8150
Bid0.7947
Ask0.8179
Day's Range0.7901 - 0.8571
52 Week Range0.6930 - 1.800
Volume192,967
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume350,437

Chart

About Femasys Inc. - Common Stock (FEMY)

Femasys Inc is a healthcare company focused on developing innovative products and solutions to enhance women's reproductive health. The company aims to address unmet medical needs in areas such as fertility and contraception through advanced medical technologies. Femasys is committed to improving patient outcomes by offering minimally invasive and user-friendly procedures, thereby empowering women with more options for their reproductive health management. Their research and development efforts are geared toward creating safer, effective, and cost-efficient treatments that can be accessible to a broader audience. Read More

News & Press Releases

12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · June 6, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · June 4, 2025
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Upstocktwits.com
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Via Stocktwits · May 30, 2025
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · May 29, 2025
What's going on in today's after hours sessionchartmill.com
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · May 29, 2025
The Latest Analyst Ratings For Femasysbenzinga.com
Via Benzinga · November 27, 2024
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.
By Femasys Inc. · Via GlobeNewswire · May 30, 2025
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement.
By Femasys Inc. · Via GlobeNewswire · May 29, 2025
Analyst Expectations For Femasys's Futurebenzinga.com
Via Benzinga · May 9, 2025
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) --
By Femasys Inc. · Via GlobeNewswire · May 8, 2025
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimisticstocktwits.com
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
Via Stocktwits · March 27, 2025
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain --
By Femasys Inc. · Via GlobeNewswire · March 27, 2025
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option
By Femasys Inc. · Via GlobeNewswire · March 19, 2025
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.
Via ACCESS Newswire · March 18, 2025
Assessing Femasys: Insights From 4 Financial Analystsbenzinga.com
Via Benzinga · March 18, 2025
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® --
By Femasys Inc. · Via GlobeNewswire · March 18, 2025
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control
By Femasys Inc. · Via GlobeNewswire · March 13, 2025
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--
By Femasys Inc. · Via GlobeNewswire · February 25, 2025
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
UK regulatory approval follows FemaSeed, FemVue and FemCerv clearance/ approvals in the U.S., Europe, Canada and Israel
By Femasys Inc. · Via GlobeNewswire · February 11, 2025
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024
By Femasys Inc. · Via GlobeNewswire · February 4, 2025
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
By Femasys Inc. · Via GlobeNewswire · January 30, 2025
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution
By Femasys Inc. · Via GlobeNewswire · January 16, 2025
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California
By Femasys Inc. · Via GlobeNewswire · December 3, 2024
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
By Femasys Inc. · Via GlobeNewswire · November 26, 2024
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
By Femasys Inc. · Via GlobeNewswire · November 12, 2024